Role of renin-angiotensin system in activation of macrophages by modified lipoproteins

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 9, 2013, Pages

  Rafatian, Naimeh ^a,b   Milne, Ross W ^a,b   Leenen, Frans H H ^a,b   Whitman, Stewart C ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Acetylated low density lipoprotein; Angiotensin II; Cholesteryl ester; Foam cells; THP 1 cells

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CATHEPSIN G; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; DIPEPTIDYL CARBOXYPEPTIDASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; RENIN; SCAVENGER RECEPTOR A;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MIGRATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FOAM CELL; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE ACTIVATION; ONCOGENE RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACETYLATED LOW-DENSITY LIPOPROTEIN; ANGIOTENSIN II; CHOLESTERYL ESTER; FOAM CELLS; THP-1 CELLS;

ACETYL-COA C-ACETYLTRANSFERASE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; CATHEPSIN G; CELL LINE, TUMOR; CHOLESTEROL ESTERS; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS A; TIME FACTORS;

EID: 84886993747     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00826.2012     Document Type: Article

References (40)

1. Agrawal S, Febbraio M, Podrez E, Cathcart MK, Stark GR, Chisolm GM. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 115: 2939-2947, 2007.
2. Barrett AJ. Cathepsin G. Methods Enzymol 80C: 561-565, 1981.
3. Biggs JR, Yang J, Gullberg U, Muchardt C, Yaniv M, Kraft AS. The human brm protein is cleaved during apoptosis: the role of cathepsin G. Proc Natl Acad Sci USA 98: 3814-3819, 2001.
4. Chao J, Blanco G, Wood JG, Gonzalez NC. Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia. Am J Physiol Heart Circ Physiol 301: H2264-H2270, 2011.
5. Daugherty A, Rateri DL, Lu H. As macrophages indulge, atherosclerotic lesions bulge. Circ Res 102: 1445-1447, 2008.
6. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110: 3849-3857, 2004.
7. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94: 2756-2767, 1996.
8. Eyries M, Agrapart M, Alonso A, Soubrier F. Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human endothelial cells via ERK1/2 pathway. Circ Res 91: 899-906, 2002.
9. Genain C, Bouhnik J, Tewksbury D, Corvol P, Menard J. Characterization of plasma and cerebrospinal fluid human angiotensinogen and des-angiotensin I-angiotensinogen by direct radioimmunoassay. J Clin Endocrinol Metab 59: 478-484, 1984.
10. Hayden JM, Brachova L, Higgins K, Obermiller L, Sevanian A, Khandrika S, Reaven PD. Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. J Lipid Res 43: 26-35, 2002.
11. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 44: 579-587, 1999.
12. Hayek T, Aviram M, Heinrich R, Sakhnini E, Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem Biophys Res Commun 273: 417-420, 2000.
13. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M. Ramipril administration to atherosclerotic mice reduces oxidized lowdensity lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 161: 65-74, 2002.
14. Kanome T, Watanabe T, Nishio K, Takahashi K, Hongo S, Miyazaki A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages. Hypertens Res 31: 1801-1810, 2008.
15. Keidar S, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 146: 249-257, 1999.
16. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236: 622-625, 1997.
17. Khachigian LM. Early growth response-1 in cardiovascular pathobiology. Circ Res 98: 186-191, 2006.
18. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 37: 587-593, 2001.
19. Klett CP, Granger JP. Physiological elevation in plasma angiotensinogen increases blood pressure. Am J Physiol Regul Integr Comp Physiol 281: R1437-R1441, 2001.
20. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, Jan Danser AH. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 52: 1076-1083, 2008.
21. Leenen FH, Skarda V, Yuan B, White R. Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol Heart Circ Physiol 276: H317-H325, 1999.
22. Leenen FH, White R, Yuan B. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol 281: H2410-H2416, 2001.
23. Li BL, Li XL, Duan ZJ, Lee O, Lin S, Ma ZM, Chang CC, Yang XY, Park JP, Mohandas TK, Noll W, Chan L, Chang TY. Human acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. J Biol Chem 274: 11060-11071, 1999.
24. Lindmark E, Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res 108: 77-84, 2002.
25. Makinen PI, Lappalainen JP, Heinonen SE, Leppanen P, Lahteenvuo MT, Aarnio JV, Heikkila J, Turunen MP, Yla-Herttuala S. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res 88: 530-538, 2010.
26. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T. Upregulation of reninangiotensin system during differentiation of monocytes to macrophages. J Hypertens 17: 537-545, 1999.
27. Osada-Oka M, Kita H, Yagi S, Sato T, Izumi Y, Iwao H. Angiotensin AT1 receptor blockers suppress oxidized low-density lipoprotein-derived formation of foam cells. Eur J Pharmacol 679: 9-15, 2012.
28. Ouimet M, Wang MD, Cadotte N, Ho K, Marcel YL. Epoxycholesterol impairs cholesteryl ester hydrolysis in macrophage foam cells, resulting in decreased cholesterol efflux. Arterioscler Thromb Vasc Biol 28: 1144-1150, 2008.
29. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800-807, 1998.
30. Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 397: 77-83, 2002.
31. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86: 1266-1272, 2000.
32. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA 103: 19794-19799, 2006.
33. Shatrov VA, Sumbayev VV, Zhou J, Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 101: 4847-4849, 2003.
34. Tiyerili V, Mueller CF, Becher UM, Czech T, van Eickels M, Daiber A, Nickenig G, Wassmann S. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knockout mice. J Mol Cell Cardiol 52: 630-637, 2012.
35. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110: 3062-3067, 2004.
36. Whatling C, Bjork H, Gredmark S, Hamsten A, Eriksson P. Effect of macrophage differentiation and exposure to mildly oxidized LDL on the proteolytic repertoire of THP-1 monocytes. J Lipid Res 45: 1768-1776, 2004.
37. Yoshida H, Quehenberger O, Kondratenko N, Green S, Steinberg D. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 18: 794-802, 1998.
38. Zhang R, Wu Y, Zhao M, Liu C, Zhou L, Shen S, Liao S, Yang K, Li Q, Wan H. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 297: L631-L640, 2009.
39. Zhao X, White R, Van Huysse J, Leenen FH. Cardiac hypertrophy and cardiac renin-angiotensin system in Dahl rats on high salt intake. J Hypertens 18: 1319-1326, 2000.
40. Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol 29: 1277-1282, 2009.